Hypochlorous acid (HOCl) is an essential signal molecule in cancer cells. Activated GRP78 ATPase by a HOCl probe named ZBM-H inhibits lung cancer cell growth. However, the role and underlying mechanism of GRP78 ATPase in lung cancer cell migration have not been established. Here, we reported that activation of GRP78 ATPase by ZBM-H suppressed A549 cell migration and inhibited EMT process. Notably, ZBM-H time-dependently decreased the protein level of integrin β4 (ITGB4) in A549 cells....

Additional file 3. Data extraction form.

Additional file 1: Figure S1. EIF4A3 was upregulated in ESCC and promoted ESCC cell proliferation and migration. (A) Relative expression of EIF4A3 in human oesophageal cancer tissues (n = 162) compared with noncancerous tissues (n = 11) and a positive correlation with SNHG16 via the GEPIA database. (B) Western blot analysis of EIF4A3 after si-NC or si-EIF4A3 transfection in ESCC cells. Mock was the blank control group. GAPDH was used as an internal control. CCK-8...

Supplementary Material 1

Topological inverse design of fabrication-constrained nanophotonic devices via adaptive projection method: supplemental document

Additional file 1: Table S1. Sequences of oligonucleotide primers used for RT-qPCR. Table S2. Organs indices of laying hens fed different biological feed additives1.

Additional file 1: Figure S1. Density plots of the self- and proxy-rating EQ-5D-3L and 5L index values. Figure S2. Bland-Altman plots of the EQ-5D-3L and the EQ-5D-5L index values Vertical Axis represents the difference between the EQ-5D-5L and EQ-5D-3L (5L minus 3L).Figure S3. Histograms of the self- and proxy-rating EQ-5D-3L and 5L index values.

Additional file 1. GRIPP2 long form.

Additional file 13: Fig. S13. Proteomic subtypes divided early-stage PDAC patients into subtypes with different prognosis, related to Fig. 6. A Summary of the relationship between proteomic subtypes and TNM stage subtypes. B Kaplan-Meier curves for overall survival of early-stage (IA and IB) PDAC patients based on 3 proteomic subtypes (log-rank test). C Bar plot indicating the enriched pathways in early-stage patients who were divided into three proteomic subtypes. D Heatmap of differentially expressed kinase...

Additional file 15: Fig. S15. Protein markers for three PDAC proteomic subtypes, related to Fig. 6. A The boxplot indicating the comparison of tumor purity across the proteomic subtypes. B Heatmap indicating the expression of protein biomarkers in the three proteomic subtypes. C Kaplan-Meier curves for overall survival based on proteomic abundance of ACOX1, S100A4 and MCM6 (log-rank test). D IHC profiling of proteomic subtype markers in PDAC. FFPE sections were stained for ACOX1, S100A4...

Additional file 16: Fig. S16. Characterization of immune infiltration in PDAC, related to Fig. 7. A Boxplot showing the age among five immune clusters. B Heatmap of xCell score between samples in old/young group of TCGA cohort. C Distribution of the percentage of proteomics subtypes across different immune subtypes (Fisher’s exact test). D The Sankey plot revealing the association between proteomics subtypes and immune subtypes. E Kaplan-Meier curves for overall survival based on immune subtypes...

Additional file 17: Fig. S17. The impact of FH amplification in PDAC, related to Fig. 7. A Scatter plot on the left presents the correlation between FH copy number and FH expression in TCGA cohort (left) or in WSU cohort (right). B, C The bar plot shows the distribution of patients with FH amplification between diabetes and non-diabetes in our cohort (B), in TCGA cohort (C, left) and in WSU cohort (C, right). D The...

Additional file 17: Fig. S17. The impact of FH amplification in PDAC, related to Fig. 7. A Scatter plot on the left presents the correlation between FH copy number and FH expression in TCGA cohort (left) or in WSU cohort (right). B, C The bar plot shows the distribution of patients with FH amplification between diabetes and non-diabetes in our cohort (B), in TCGA cohort (C, left) and in WSU cohort (C, right). D The...

Additional file 19: Fig. S19. Biological diversity between high and low purity samples. A The heatmap indicating the correlation between histological purity and purity assessed by ESTIMATE and ABSOLUTE package. B The expression heatmap describing differentially expressed proteins and phosphoproteins in high/low tumor purity. The enriched biological pathways are annotated on the right.

Additional file 1: Fig. S1. Quality assessment of proteomic data of PDAC, related to Fig. 1. A-D. The number of identified mRNA (A), protein (B), phosphoprotein (C) and phosphosite (D) in the tumors and NATs. E Trinucleotide motif frequency plots and mutations frequency similarity of identified five mutational profiles (Fudan cohort). F Trinucleotide motif frequency plots and mutations frequency similarity of identified five mutational profiles (CPTAC cohort). G Spearman’s correlation analysis of 16 HEK293T cell...

Additional file 4: Fig. S4. Characteristics of PDAC patients with KRASG12D mutations. A The volcano plot showing the phosphosites that significantly altered between tumors with KRASG12D and with other types of KRAS mutations. B The heatmap indicating the phosphorylation abundance of RAF1, MAP2K2, MAPK1 across tumors with different KRAS mutations. C Kaplan-Meier curves for overall survival based on the phosphorylation of E2F1 at S364 (left) and based on the TF activity of E2F1 (right). D...

Additional file 5: Fig. S5. Integrated multi-omics features in tumor tissues compared with NATs of the PDAC, related to Fig. 3. A Principal component analysis (PCA) of RNA-Seq (19,992 genes) in 54 tumors and 51 NATs. Red, tumors; blue, NATs. B PCA of 7,399 phosphoproteins in 113 paired samples. Red, tumors; blue, NATs. C A volcano plot showing the results of a two-tailed Student’s t test comparing tumors and NATs at transcriptome level. D A...

Additional file 6: Fig. S6. Proteomic features in tumor tissues compared with NATs of the PDAC in CPTAC cohort, related to Fig. 3. A Venn diagram summary of the number of up-regulated (left) and down-regulated (right) proteins between Fudan cohort and CPTAC cohort. B Differentially expressed proteins in tumors and NATs in CPTAC cohort (right panel). The left panel shows KEGG pathway analysis of identified differentially expressed proteins. Red, up-regulated pathways; blue, down-regulated pathways. C...

Additional file 7: Fig. S7. The expression of phosphotyrosine in PDAC cohort, related to Fig. 3. A. The proportion of phosphorylation sites S, T and Y in tumors and NATs, respectively. B. The comparison of the percentage of phosphorylation sites S, T and Y in Fudan cohort and other gastrointestinal tumor cohorts. C. The scatter plot demonstrating the T/NAT ratio of phosphotyrosine (y axis) and T/NAT ratio of their corresponding proteins (x axis). D. Heatmap...

Supplemental material, sj-docx-2-han-10.1177_15589447221128982 for Routine Pathological Examination of Clinically Presumed Dupuytren Disease: Does It Add Value? by Kathryn Uhlman, Michael Bonert, Jessica Murphy, Eric Duku, Asghar Naqvi and Achilles Thoma in HAND

Supplemental material, sj-docx-3-han-10.1177_15589447221128982 for Routine Pathological Examination of Clinically Presumed Dupuytren Disease: Does It Add Value? by Kathryn Uhlman, Michael Bonert, Jessica Murphy, Eric Duku, Asghar Naqvi and Achilles Thoma in HAND

Supplemental material, sj-docx-3-han-10.1177_15589447221128982 for Routine Pathological Examination of Clinically Presumed Dupuytren Disease: Does It Add Value? by Kathryn Uhlman, Michael Bonert, Jessica Murphy, Eric Duku, Asghar Naqvi and Achilles Thoma in HAND

Supplementary Material 1. Supplementary Tables 1-8; Supplementary Figures 1-5.

Additional file 3. Evidence to Decision tables.

Supplemental material, sj-docx-1-sat-10.1177_11782218221126977 for Characterizing Clinical Heterogeneity in a Large Inpatient Addiction Treatment Sample: Confirmatory Latent Profile Analysis and Differential Levels of Craving and Impulsivity by Meenu Minhas, Alysha Cooper, Sarah Sousa, Mary Jean Costello and James MacKillop in Substance Abuse: Research and Treatment